Zevra Therapeutics opened lower at $11.75, compared with its previous close of $11.85. In the last trading session, the stock traded between $11.16 and $11.77. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Zevra Therapeutics is now worth
$ 204.95
Giving a profit of
$ 104.95 (104.95%)
Invest with $1
Note: Past profits do not guarantee future returns.
Adjusted EPS of $0.176 beat the $0.16 analyst estimate. Total net revenue rose 45% YoY to $37.8 million. Net income turned positive at $19.2 million vs prior year loss. MIPLYFA US sales contributed $34.0 million to topline.
9 days ago
20Oct
Zevra Therapeutics to report Q3FY26 results on November 3
Zevra Therapeutics will release Q3FY26 results on November 3, 2026. Conference call scheduled for 4:30 pm ET following the market close. Webcast replay available for 90 days via investor relations portal.
23 days ago
25Aug
Zevra presents long-term MIPLYFFA data for NPC at SSIEM 2026
Zevra presents two posters on MIPLYFFA for NPC at SSIEM 2026. U.S. data shows stable disease scores at year 4 (11.6 vs 11.6 baseline). German program covers 48 patients with up to 8 years of treatment. No discontinuations due to arimoclomol-related side effects reported. EMA Marketing Authorization Application is under evaluation.
2mo ago
20Aug
HC Wainwright reiterates Buy on Zevra Therapeutics, keeps $26 target
HC Wainwright & Co. analyst Brandon Folkes reiterates a Buy rating on Zevra Therapeutics (NASDAQ: ZVRA) and maintains the $26 price target. The update reflects the broker's ongoing positive outlook on the stock without disclosing new financial data or operational changes.
2mo ago
6Aug
Zevra Therapeutics enrolls four patients in Phase 3 trial
Zevra Therapeutics advanced its Phase 3 DiSCOVER trial for celiprolol by enrolling four patients in Q2 2026, reaching a total of 66 participants. With three confirmed events, the company plans to engage with the FDA in H2 2026 to discuss accelerating clinical development pathways.
3mo ago
6Aug
Zevra Therapeutics Q2 Results: Sales rise 53% YoY to $39.663M
Zevra Therapeutics delivered a mixed but estimate-beating Q2 report. Adjusted EPS of $0.25 surpassed the $0.14 consensus by 78.57%, though it dropped 79.84% YoY from $1.24. Sales jumped 53.14% YoY to $39.663 million, beating the $33.572 million forecast by 18.14%, highlighting strong revenue growth amidst margin compression.
